47 Recruiting Ovarian Cancer Phase 2 Clinical Trials
Active phase 2 studies for ovarian cancer enrolling across the USA. Verify eligibility and contact site coordinators.
All Ovarian Cancer studiesPhase 2 Studies for Ovarian Cancer
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View Study & Checklist ➔Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
View Study & Checklist ➔ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
📍 Honor Health — Scottsdale, Arizona
View Study & Checklist ➔A Trial of Vigil for Participants With Ovarian Cancer
📍 University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
View Study & Checklist ➔A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
📍 Tom Baker Cancer Centre — Calgary, Alberta
View Study & Checklist ➔A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
📍 Cancer Treatment Centers of America, Phoenix. 403 — Goodyear, Arizona
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
📍 UCSF Helen Diller Family CCC — San Francisco, California
View Study & Checklist ➔Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
📍 Research Site — Stanford, California
View Study & Checklist ➔Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer
📍 University of Texas MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
📍 The University of Arizona Cancer Center — Tucson, Arizona
View Study & Checklist ➔PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
📍 Arizona Oncology Associates, PC - NAHOA — Prescott, Arizona
View Study & Checklist ➔EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
📍 Research Site — Boston, Massachusetts
View Study & Checklist ➔BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
📍 University of Illinois Chicago — Chicago, Illinois
View Study & Checklist ➔Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer
📍 UMPC Hillman Cancer Center — Pittsburgh, Pennsylvania
View Study & Checklist ➔Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab
📍 Medical University of South Carolina Hollings Cancer Center — Charleston, South Carolina
View Study & Checklist ➔A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
📍 University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
View Study & Checklist ➔Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
📍 Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center — Cleveland, Ohio
View Study & Checklist ➔Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
📍 Icahn School of Medicine at Mount Sinai Division of Hematology and Medical Oncology — New York, New York
View Study & Checklist ➔Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
📍 Start Cal — Los Angeles, California
View Study & Checklist ➔Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
📍 Research Site — Duarte, California
View Study & Checklist ➔A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
📍 Usa Health Mitchell Cancer Institute — Mobile, Alabama
View Study & Checklist ➔Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
📍 O'Neal Comprehensive Cancer Center at UAB — Birmingham, Alabama
View Study & Checklist ➔A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer
📍 Abbotsford Centre, BC Cancer Agency — Abbotsford British Columbia, British Columbia
View Study & Checklist ➔A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
📍 UC San Diego Health - Moores Cancer Center /ID# 277574 — La Jolla, California
View Study & Checklist ➔Autophagy Maintenance (AUTOMAIN)
📍 Medical University of South Carolina — Charleston, South Carolina
View Study & Checklist ➔Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
📍 The University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT
📍 Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange, California
View Study & Checklist ➔A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
📍 City of Hope Comprehensive Cancer Center — Duarte, California
View Study & Checklist ➔Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
📍 Brigham and Women's Hospital — Boston, Massachusetts
View Study & Checklist ➔A Study of Isoquercetin in People With Ovarian Cancer
📍 Beth Israel Deaconess Medical Center (Data Collection Only) — Boston, Massachusetts
View Study & Checklist ➔Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
📍 Sunnybrook Research Institute — Toronto, Ontario
View Study & Checklist ➔A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
📍 Georgia Cancer Center at Augusta University — Augusta, Georgia
View Study & Checklist ➔Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
📍 Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
📍 The University of Chicago Medical Center — Chicago, Illinois
View Study & Checklist ➔Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
📍 Dartmouth Hitchcock — Lebanon, New Hampshire
View Study & Checklist ➔Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
📍 University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
View Study & Checklist ➔FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
📍 The University of Alabama — Birmingham, Alabama
View Study & Checklist ➔Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
📍 University of Alabama at Birmingham Womens & Infants Center — Birmingham, Alabama
View Study & Checklist ➔Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
📍 004 — Birmingham, Alabama
View Study & Checklist ➔Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
📍 University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio
View Study & Checklist ➔Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
📍 Loyola University Medical Center — Maywood, Illinois
View Study & Checklist ➔Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
📍 Johns Hopkins Medicine SKCCC — Baltimore, Maryland
View Study & Checklist ➔